National Institutes of Health (NIH) will launch a Phase III multidrug-resistant TB (MDR-TB) prevention clinical trial-Phoenix- in 12 high tuberculosis burden countries including India.
The announcement was made at the 50th Union World Conference on Lung Health (WCOLH), held at Hyderabad, India.
NIH has committed $70 million for the trial focusing people at high risk, especially children and adults who are exposed to members with the disease in households.
In India, the trial is to be launched in Pune and Chennai. The study is carried out in a public-private partnership involving Otsuka Pharmaceuticals, Japan, reports said.
The project is called PHOENIx MDR-TB or Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients.
People at high risk for MDR-TB with latent TB infection, HIV or other factors, or those younger than age 5 years will be involved in the study.
The trial will compare the safety and efficacy of the TB drug delamanid, with the existing drug isoniazid for preventing active MDR-TB.
The study is co-funded by NIAID and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.